Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
about
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.Primary central nervous system lymphoma: three linked questions in the situation puzzle of radiotherapy.Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.Long-term survival of diffuse large B cell lymphoma of the trigeminal region extending to the Meckel's cave treated by CHASER therapy: case report.Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.Temozolomide as salvage treatment in primary brain lymphomas.Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 - a single centre reportArea under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004.A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.Treatment approaches for primary CNS lymphomas.Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCTRadiation therapy for primary central nervous system lymphoma.III. Current concepts in primary central nervous lymphoma.Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate.High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.Post-treatment T1 shortening in primary CNS lymphoma.Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience.Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).Differentiating enhancing multiple sclerosis lesions, glioblastoma, and lymphoma with dynamic texture parameters analysis (DTPA): A feasibility study.Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
P2860
Q33347138-0CD3539C-76E6-4C06-BD48-108E69BE0AE3Q33359199-0116E92F-7E0E-45DF-A259-7233712921ECQ33396041-B8ADC8C8-5B5B-4BE7-8543-B6CBD6106FE9Q34753447-F820F32D-7957-4E70-B5F6-EA7C20DAE64CQ35825003-4EF9A1BF-8D0E-4CB6-8419-95A5D6129D87Q35943978-8C2CE233-C0B6-4990-B208-7071EF0B17B0Q36492327-52D8EEC0-78E6-4868-AB22-4148850C05A0Q36610071-1E8DE928-4D30-4601-BBD0-AA8EC756478CQ36611270-AB6E57B1-1DC5-40C2-8D7E-1266B930A61AQ36694435-950096CA-D05E-4C09-9E22-D2B6615276A3Q37151981-62E3EB12-4C8E-4A7B-8460-98536743CD50Q37183305-B40C82FE-6F07-4C41-AFE7-EC9FB9B0B0BAQ37739428-20C56A60-7646-48FD-959C-8F03C4CC51FAQ37946249-F3CBD161-EBCF-4317-85A7-DB8B6CD24D06Q38493171-EF9E3D14-AE62-43E7-9A95-6DA1B6496C8FQ38523967-6EE82468-AD31-4488-903F-00E6AD58F3B4Q42714104-A0C0F689-5A27-437E-A58A-E4AC9FD24634Q44401515-FAB3CF44-049F-43A0-B7AB-2470F857BDACQ44437452-3A62D10B-B04C-4E6A-9124-E6C9BEC234D0Q45215887-B4AE3E74-A273-4752-9552-D24B399FC493Q47553512-93AD6C73-7A7B-4ABC-8095-92C704E8C8B9Q47692369-EEF07244-0CBB-44BA-BE9B-C24398FC1D1CQ47830783-2A893468-E895-47AB-ADFC-732EB0D88B0BQ50913370-15812D0F-3EB3-4B45-AF98-AAB105C3DAD2Q57301962-9E0207B8-C91D-4675-8EAC-6D9D1978CB41
P2860
Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Therapeutic management of prim ...... ssons from prospective trials.
@ast
Therapeutic management of prim ...... ssons from prospective trials.
@en
Therapeutic management of prim ...... ssons from prospective trials.
@nl
type
label
Therapeutic management of prim ...... ssons from prospective trials.
@ast
Therapeutic management of prim ...... ssons from prospective trials.
@en
Therapeutic management of prim ...... ssons from prospective trials.
@nl
prefLabel
Therapeutic management of prim ...... ssons from prospective trials.
@ast
Therapeutic management of prim ...... ssons from prospective trials.
@en
Therapeutic management of prim ...... ssons from prospective trials.
@nl
P2093
P356
P1433
P1476
Therapeutic management of prim ...... ssons from prospective trials.
@en
P2093
P304
P356
10.1023/A:1008376412784
P577
2000-08-01T00:00:00Z